Company profile
Avicanna Inc.
OTC: AVCNF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#561 of 1,418 Healthcare companies by revenue38th-percentile growth
EA Score
55CFH 57DQ —GM 54SS 45
v0.1 · 45/100 weight · provisional
↑ 3-yr revenue growth, return on assets · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$18.3M
Rev growth YoY (TTM)
+0.8%
Net income (FY)
-$2.0M
Employees
112
as of 2026-08-22
Market cap
$12.2M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$18.2M25.5M CAD2025
Net income-$2.0M-2.8M CAD2025
Operating income-$1.9M-2.7M CAD2025
Total assets$15.5M21.2M CAD2025
Liabilities$7.2M9.8M CAD2025
Equity$2.1M2.8M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Avicanna Inc.’s revenue?
Avicanna Inc. booked $18.2M in FY2025 revenue, contracting 2.0% year over year — slower than 62% of Healthcare companies we track, at a -11.2% net margin.
Peers · Healthcare
OmniAb, Inc.50DFuse Medical, Inc.——PD-Rx Pharmaceuticals, Inc.70BTrees Corporation——Marpai, Inc.34DResponse Genetics, Inc——Key facts
CEOAras Azadian Mba
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: AVCNF
Employees112
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.